

For immediate release

## IOL Chemicals and Pharmaceuticals Reports Q2 FY23 Results

- Total Income stood at Rs 546 Cr against Rs. 570 Cr QoQ and Rs 548 Cr YoY
- EBITDA at Rs. 37 Cr as compared to Rs. 61 Cr QoQ and Rs 54 Cr YoY
- Net profit of the Company at Rs 15.6 Cr against Rs. 34.9 Cr QoQ and Rs. 30.8 Cr YoY

**14<sup>th</sup> November, 2022, Ludhiana:**

IOL Chemicals and Pharmaceuticals Limited, a leading manufacturer of pharmaceutical (APIs) and specialty chemicals reported results for the second quarter ended September 30, 2022 as highlighted herein below:

### Q2FY23 Financial Highlights

(Rs in Crore)

Particulars	Q2 FY23	Q1 FY23	QoQ % Change
<b>Total Income</b>	546.47	570.16	-4.15
<b>EBITDA</b>	36.73	61.17	-39.95
<b>EBITDA Margin (%)</b>	6.72%	10.73%	-4.01
<b>PAT</b>	15.67	34.89	-55.09

*Commenting on the performance of the Company during the quarter, Dr Sanjay Chaturvedi, Executive Director & CEO said, "The global economy is going through a roller-coaster ride as central banks battle inflation through rate hikes. Apart from inflation, the global trade is also impacted by uncertain business environment following Russia's invasion of Ukraine and frequent lockdowns in China, thereby leading to supply chain disruptions.*

*For the Indian API manufacturers and specialty chemicals players, the major challenge comes from volatile input costs with raw material and energy prices both impacting the profitability. However, we expect the headwinds to subside going into the second half of this financial year and strongly believe that the worst is behind us in terms of challenges. IOL Chemicals has improved the operational efficiency over last few quarters and we believe this would give us an edge in terms of expanding our margins next quarter onwards."*

During the quarter under review, the Company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA in accordance with EU REACH Regulation on Chemicals and their Safe Use. This certification allows the Company to export Ethyl Acetate across all the countries in European Union.

The Company has invested US\$2.1 million in USpharma Limited, an USA based Company that develop novel drug delivery technologies.

EDQM Authority issued CEP Certificate for Pantoprazole Sodium Sesquihydrate and Levetiracetam. This will enable the Company to export in European Market. The Company has been granted Patent on “Sitagliptin Process” from Indian Patent Office, Government of India on 2<sup>nd</sup> November 2022

### **About IOL Chemicals and Pharmaceuticals Limited (IOLCP)**

Company was established in 1986, listed on National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164) is one of the leading pharmaceutical (APIs) Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, antidiabetes, anti-cholesterol and anti-platelets.

The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World’s largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with 17 MW captive Co-Generation plant for self - reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

### **Disclaimer:**

*This document may contain statement which reflect management’s current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.*